Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705273 | 0.87 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL4781373 | 0.83 | KMT2A (0.48) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL2705838 | 0.77 | MEN1 (0.55) | ALDH1A1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL25429745 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL1292014 | 0.72 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL28556938 | 0.70 | MMP2 (0.43) | MEN1KMT2APSEN1PSEN2APH1B | |
| SCHEMBL2702557 | 0.70 | PSEN1 (0.52) | ALDH1A1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL2702631 | 0.70 | PSEN1 (0.56) | ALDH1A1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL16723452 | 0.69 | MAPT (0.43) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL5027897 | 0.68 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450358-A1 | Fused, tricyclic sulfonamide inhibitors of gamma secretase | Elan Pharmaceuticals Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2038280-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | ALDH1A1 1779/4885MEN1 2805/4885KMT2A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.